TRACON Pharmaceuticals (NASDAQ:TCON) issued its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.46) by $0.09, Bloomberg Earnings reports. TRACON Pharmaceuticals had a negative return on equity of 83.43% and a negative net margin of 201.21%.
Shares of TRACON Pharmaceuticals (TCON) traded up $0.02 during trading on Thursday, hitting $2.22. The stock had a trading volume of 184,100 shares, compared to its average volume of 224,381. The stock has a market capitalization of $38.53, a P/E ratio of -1.82 and a beta of 2.06. TRACON Pharmaceuticals has a 12-month low of $2.00 and a 12-month high of $4.70. The company has a current ratio of 3.80, a quick ratio of 3.80 and a debt-to-equity ratio of 0.24.
Separately, Zacks Investment Research raised TRACON Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.25 price objective for the company in a research note on Saturday, November 11th.
ILLEGAL ACTIVITY WARNING: This article was originally published by Ticker Report and is the property of of Ticker Report. If you are viewing this article on another publication, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this article can be accessed at https://www.tickerreport.com/banking-finance/3230560/tracon-pharmaceuticals-tcon-issues-earnings-results-beats-estimates-by-0-09-eps.html.
TRACON Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (wet AMD) and fibrotic diseases. The Company’s research focuses on antibodies that bind to the endoglin receptor, which is essential to angiogenesis (the process of new blood vessel formation) and a contributor to fibrosis (tissue scarring).
Receive News & Ratings for TRACON Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRACON Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.